中国药物经济学2026，Vol.21Issue(1)：106-110,115,6.DOI:10.12010/j.issn.1673-5846.2026.01.022
血清25-羟维生素D3水平与免疫检查点抑制剂免疫相关不良反应的相关性
Association between Serum 25-Hydroxyvitamin D3 Levels and Immune-Related Adverse Event Induced by Immune Checkpoint Inhibitors
摘要
Abstract
Objective To explore the correlation between serum 25-hydroxyvitamin D3[25-(OH)D3]levels and the risk and severity of immune-related adverse event(irAE)caused by immune checkpoint inhibitors(ICIs).Methods A total of 148 patients with advanced malignant tumors who received ICIs treatment and were admitted to Panzhihua Central Hospital from August 2022 to February 2025 were selected.The serum 25-(OH)D3 levels of the patients before treatment were detected,and the association between it and the incidence and severity of irAE was analyzed.Results The incidence of irAE in the serum 25-(OH)D3 deficiency group(＜10 ng/ml)was significantly higher than that in the normal group(P＜0.05),and 25-(OH)D3 was an independent protective factor for irAE(OR=0.91,95%CI:0.86～0.96,P=0.001),the ratio of small plate count to lymphocyte count(PLR)was an independent risk factor for irAE(OR=1.82,95%CI:1.10～3.01,P=0.019).Conclusion Serum 25-(OH)D3 level is an important risk factor for irAE in ICIs.Timely monitoring of 25-(OH)D3 level or supplementation of vitamin D3 may provide new evidence for the prevention of irAE.关键词
25-羟维生素D3/免疫检查点抑制剂/免疫/不良反应Key words
25-Hydroxyvitamin D3/Immune checkpoint inhibitors/Immune/Adverse events分类
医药卫生引用本文复制引用
万玲俐,程晓伟,高云,赵国江,胡书源,赖忠明,袁野,毛光明..血清25-羟维生素D3水平与免疫检查点抑制剂免疫相关不良反应的相关性[J].中国药物经济学,2026,21(1):106-110,115,6.基金项目
攀枝花市科学技术局市级指导性科技计划项目(2024ZD-S-25) （2024ZD-S-25）
攀枝花市中心医院院内科研课题(202308) （202308）
